Drug Profile
Research programme: cell penetrating and interfering peptides - CleveXel Pharma/PEP-Therapy
Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator CleveXel Pharma; PEP-Therapy
- Class Antineoplastics; Peptides
- Mechanism of Action Caspase 9 inhibitors; Protein phosphatase 2A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Cancer in France (unspecified route)
- 28 May 2019 No recent reports of development identified for preclinical development in Cancer in France
- 27 Apr 2015 Preclinical trials in Cancer in France (unspecified route)